Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dannex Ayrton StarwinXGHA:DASPHARMA +4.27%7 Earnings per Share (Diluted) is GHS as of . 20. GuruFocus rates XGHA:DASPHARMA with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 786 Drug Manufacturers companies, Dannex Ayrton Starwin ranks worse than 127226.34% on this metric.
Dannex Ayrton Starwin (XGHA:DASPHARMA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Dannex Ayrton Starwin Earnings per Share (Diluted) Related Terms
Dannex Ayrton Starwin Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Dannex Ayrton Starwin's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dannex Ayrton Starwin Earnings per Share (Diluted) Chart
Dannex Ayrton Starwin Annual Data
Trend
Earnings per Share (Diluted)
Dannex Ayrton Starwin Quarterly Data
Earnings per Share (Diluted)
XGHA:DASPHARMA vs : Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dannex Ayrton Starwin's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dannex Ayrton Starwin PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dannex Ayrton Starwin's PE Ratio distribution charts can be found below:
* The bar in red indicates where Dannex Ayrton Starwin's PE Ratio falls into.
Dannex Ayrton Starwin Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Dannex Ayrton Starwin's Earnings Per Share (Diluted) for the fiscal year that ended in . 20 is calculated as
What does a Earnings per Share (Diluted) of GHS mean?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a Earnings per Share (Diluted) of GHS as of . 20. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Dannex Ayrton Starwin and its competitors. According to the industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 786 companies in the Drug Manufacturers industry.
Is Dannex Ayrton Starwin's Earnings per Share (Diluted) too high?
Dannex Ayrton Starwin's current Earnings per Share (Diluted) is GHS. Based on the distribution chart, Dannex Ayrton Starwin ranks #999999 out of 786 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Dannex Ayrton Starwin has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Dannex Ayrton Starwin's Earnings per Share (Diluted) compare to ?
According to the Drug Manufacturers industry distribution chart, Dannex Ayrton Starwin ranks #999999 out of 786 companies for Earnings per Share (Diluted). This places Dannex Ayrton Starwin in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.65, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Dannex Ayrton Starwin and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dannex Ayrton Starwin's current Earnings per Share (Diluted) is GHS. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dannex Ayrton Starwin stock overvalued right now?
Dannex Ayrton Starwin (XGHA:DASPHARMA) has a current Earnings per Share (Diluted) of GHS. The current Earnings per Share (Diluted) is GHS. Dannex Ayrton Starwin's overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Dannex Ayrton Starwin (XGHA:DASPHARMA), the current Earnings per Share (Diluted) is GHS as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Dannex Ayrton Starwin PLC is a pharmaceutical company. The company offers a product range that includes tablets, capsules, liquids syrups and suspensions, powders, ointments, and chemicals. It also manufactures and distributes Vitamin C.
7GF Score
Get the complete analysis for XGHA:DASPHARMA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:DASPHARMA has been successfully added to your 
